← Eichor
Study identifier: NCT07562282 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Safety and Efficacy of Combination of Tamsulosin 0.4 mg Plus Tadalafil 5mg Versus 2.5 mg

Condition: Kidney Stone · Ureteric Stone  ·  Sponsor: Ain Shams University

PhaseNA
Planned participants140
Who can joinAll sexes, 18 Years to 71 Years
Healthy volunteersNo

About this study

Ureteral stenting is a common urological procedure performed to relieve obstruction and facilitate urinary drainage. Despite its effectiveness, stent-related symptoms (SRS) such as dysuria, frequency, urgency, flank pain, and sexual discomfort negatively affect patient quality of life. Pharmacological management with alpha-blockers such as Tamsulosin and phosphodiesterase-5 inhibitors (PDE5i) such as Tadalafil has shown promise in reducing SRS. While low-dose Tadalafil (2.5 mg) has not been explored, its comparative effectiveness against the standard 5 mg dose when combined with Tamsulosin remains under-researched. This study aims to evaluate the difference in reduction of SRS between Tamsulosin with Tadalafil in standard and half dosage.

This description comes directly from the study's public registry record.

Talk to the study team

Ahmed Amr Mohammed Mounier, MSc  ·  +201111984645  ·  160022@med.asu.edu.eg

Waleed Mousa, Professor  ·  +201067628771  ·  Waleedmousa@med.asu.edu.eg

Always discuss trial participation with your own doctor first.

Locations (1)

Ain Shams University HospitalCairo, Abbasia, EgyptRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07562282